<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-U60RVYI0</identifier><date>2019</date><creator>Krošelj, Marko</creator><relation>documents/doc/U/URN_NBN_SI_doc-U60RVYI0_001.pdf</relation><relation>documents/doc/U/URN_NBN_SI_doc-U60RVYI0_001.txt</relation><format format_type="issue">2</format><format format_type="volume">70</format><format format_type="type">article</format><format format_type="extent">str. 80-86</format><identifier identifier_type="ISSN">0014-8229</identifier><identifier identifier_type="COBISSID_HOST">6193324</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-U60RVYI0</identifier><language>slv</language><publisher>Slovensko farmacevtsko društvo</publisher><source>Farmacevtski vestnik</source><rights>InC</rights><subject language_type_id="slv">bolezni ščitnice</subject><subject language_type_id="slv">nuklearna medicina</subject><subject language_type_id="slv">radiofarmaki</subject><subject language_type_id="slv">radiojod</subject><subject language_type_id="slv">varstvo pred sevanji</subject><title>Radiofarmaki v obravnavi bolezni ščitnice</title><title>Radiopharmaceuticals in the management of thyroid disease</title></Record>